tiprankstipranks
Advertisement
Advertisement

TARA Stock Latest News

Is TARA a Buy, Before Earnings?
Pre-EarningsIs TARA a Buy, Before Earnings?
6d ago
TARA
uniQure, Protara, Abeona, Cerebras, Verisign Insider Shake-Up
PremiumWeekend Updates
uniQure, Protara, Abeona, Cerebras, Verisign Insider Shake-Up
30d ago
ABEO
CBRS
Protara Therapeutics Announces Key Medical Leadership Transition
PremiumCompany Announcements
Protara Therapeutics Announces Key Medical Leadership Transition
1M ago
8K
TARA
Protara Therapeutics Stockholders Approve Governance and Share Increases
PremiumCompany Announcements
Protara Therapeutics Stockholders Approve Governance and Share Increases
2M ago
8K
TARA
Protara Therapeutics price target raised to $28 from $25 at Oppenheimer
PremiumThe Fly
Protara Therapeutics price target raised to $28 from $25 at Oppenheimer
2M ago
TARA
Peaker Reiterates Buy on TARA-002 After Strong STARBORN-2 Data, Sets $25 Price Target on Accelerated Approval Potential
PremiumRatingsPeaker Reiterates Buy on TARA-002 After Strong STARBORN-2 Data, Sets $25 Price Target on Accelerated Approval Potential
2M ago
TARA
Unusually active option classes on open May 15th
Premium
The Fly
Unusually active option classes on open May 15th
3M ago
AGQ
CSX
Protara announces updated 12-month data from Cohort A of ADVANCED-2 trial
Premium
The Fly
Protara announces updated 12-month data from Cohort A of ADVANCED-2 trial
3M ago
TARA
Protara Therapeutics price target lowered to $26 from $27 at JPMorgan
PremiumThe Fly
Protara Therapeutics price target lowered to $26 from $27 at JPMorgan
3M ago
TARA
Protara Therapeutics files $300M mixed securities shelf
PremiumThe Fly
Protara Therapeutics files $300M mixed securities shelf
3M ago
TARA
Protara Therapeutics reports Q1 EPS (31c), consensus (37c)
PremiumThe Fly
Protara Therapeutics reports Q1 EPS (31c), consensus (37c)
3M ago
TARA
JPMorgan healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
JPMorgan healthcare analysts hold an analyst/industry conference call
4M ago
CGON
TARA
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results
PremiumCompany AnnouncementsProtara Therapeutics Highlights Positive TARA-002 Phase 2 Results
4M ago
8K
TARA
Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway
Premium
Ratings
Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway
5M ago
TARA
Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028
Premium
Ratings
Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028
5M ago
TARA
Protara Therapeutics reports Q4 EPS (37c), consensus (31c)
PremiumThe Fly
Protara Therapeutics reports Q4 EPS (37c), consensus (31c)
5M ago
TARA
Protara Therapeutics sees cash runway into 2028
PremiumThe Fly
Protara Therapeutics sees cash runway into 2028
5M ago
TARA
TARA Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
TARA Upcoming Earnings Report: What to Expect?
5M ago
TARA
De-Risked Lead Asset and Underappreciated Pipeline Upside Support Buy Rating on Protara
PremiumRatings
De-Risked Lead Asset and Underappreciated Pipeline Upside Support Buy Rating on Protara
5M ago
TARA
Protara Therapeutics initiated with an Overweight at JPMorgan
PremiumThe FlyProtara Therapeutics initiated with an Overweight at JPMorgan
5M ago
TARA
Protara Highlights Strong Phase 2 Data for TARA-002
Premium
Company Announcements
Protara Highlights Strong Phase 2 Data for TARA-002
5M ago
8K
TARA
Reframing TARA‑002’s Potential: Underappreciated Durability and Commercial Upside in BCG‑Unresponsive NMIBC
Premium
Ratings
Reframing TARA‑002’s Potential: Underappreciated Durability and Commercial Upside in BCG‑Unresponsive NMIBC
5M ago
TARA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >